Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
27.61
-1.95 (-6.61%)
At close: Aug 1, 2025, 4:00 PM
27.73
+0.12 (0.45%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts that cover Revance Therapeutics stock have a consensus rating of "Hold" and an average price target of $46.76, which forecasts a 69.39% increase in the stock price over the next year. The lowest target is $25 and the highest is $80.
Price Target: $46.76 (+69.39%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 14 | 14 | 13 | 13 | 13 | 13 |
| Sell | 3 | 3 | 3 | 3 | 4 | 4 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 19 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Sell Maintains $26 → $25 | Sell | Maintains | $26 → $25 | -9.44% | Jul 22, 2025 |
| JP Morgan | JP Morgan | Sell Maintains $33 → $26 | Sell | Maintains | $33 → $26 | -5.81% | May 22, 2025 |
| UBS | UBS | Strong Buy Maintains $78 → $70 | Strong Buy | Maintains | $78 → $70 | +153.58% | May 2, 2025 |
| Barclays | Barclays | Hold Maintains $45 → $40 | Hold | Maintains | $45 → $40 | +44.90% | May 2, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $32 → $28 | Hold | Maintains | $32 → $28 | +1.43% | May 2, 2025 |
Financial Forecast
Revenue This Year
2.12B
from 3.24B
Decreased by -34.43%
Revenue Next Year
2.34B
from 2.12B
Increased by 10.04%
EPS This Year
-10.34
from -9.28
EPS Next Year
-7.82
from -10.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.6B | 3.8B | 4.3B | ||
| Avg | 2.1B | 2.3B | 2.8B | ||
| Low | 1.7B | 1.3B | 1.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -20.1% | 81.0% | 86.0% | ||
| Avg | -34.4% | 10.0% | 21.6% | ||
| Low | -48.1% | -37.4% | -25.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -8.65 | -5.10 | -2.23 | ||
| Avg | -10.34 | -7.82 | -5.03 | ||
| Low | -11.17 | -9.58 | -7.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.